Efficacy and Cardiovascular Safety of Topical Timolol, Brimonidine & Latanoprost in Newly Diagnosed Patients of Open Angle Glaucoma.
Loading...
Date
2013-01
Authors
Kapoor, Kiran
Khajuria, Vijay
Kapoor, B
Gupta, Satish
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
The present study was conducted in chronic open angle glaucoma patients to evaluate their efficacy in
reducing IOP and their cardiovascular safety. 48 newly diagnosed patients of glaucoma completed the
trial. Patients were divided into three groups and received medications in form of topical instillations.
Group I (Timolol 0.5% twice a day), Group II (Brimonidine Tatrate 0.2% twice a day) & Group III
(Latanoprost 0.005% once a day) for 12 weeks. All the three medications, significantly decreased IOP
(P<0.05), however, Latanoprost caused maximum decrease in IOP, followed by Brimonidine and Timolol.
Visual Acquity was not affected by any of the medication. Pulse Rate and PR Interval were decreased
in Timolol group significantly (P < 0.001) while Brimonidine and Latanoprost did not alter Pulse Rate.
Blood Pressure was not affected by either of medication except Brimonidine which caused reduction in
systolic Blood Pressure at 12 weeks. The results of present study demonstrates superiority of Latanoprost
over Timolol and Brimonidine as it lacked effect on Pulse Rate, Blood Pressure and HR, besides being
more efficacious.
Description
Keywords
Glaucoma, Latanoprost, Brimonidine, Timolol, IOP, Pulse Rate, HR, PR-Interval
Citation
Kapoor Kiran, Khajuria Vijay, Kapoor B, Gupta Satish. Efficacy and Cardiovascular Safety f Topical Timolol, Brimonidine & Latanoprost in Newly Diagnosed Patients of Open Angle Glaucoma. JK Science Journal of Medical Education and Research. 2013 Jan-Mar;15(1): 15-18.